Evidence map›Paper›PMID 33717210›Full record

ReviewTherapeutic advances in gastroenterology2021

Intestinal barrier dysfunction in irritable bowel syndrome: a systematic review.

Nikita Hanning, Adam L Edwinson, Hannah Ceuleers, Stephanie A Peters, Joris G De Man, Leslie C Hassett, Benedicte Y De Winter, Madhusudan Grover

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Therapeutic advances in gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06676488 (A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome), which is not on this map. Cited by 130 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
130citing papers in PubMed, 1 pooled it
18.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06676488 nacompletednot on this mapstarted 2025, after this paper: background citation

A Randomized Crossover Trial of Bright Light Therapy in Irritable Bowel Syndrome

TypeinterventionalSponsorMedical University of South CarolinaRan2025 to 2026Enrolled5ConditionsIrritable Bowel Syndrome (IBS), Circadian MisalignmentArmsRe-Timer glasses, Placebo Device
3 · Its place in the literature

Who cites it

130 citing papers in PubMed, 1 synthesis or guideline pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Eight weeks of treatment with probioticFrontiers in nutrition · 2025
    Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

70 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Nikita HanningDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Adam L EdwinsonDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Hannah CeuleersLaboratory of Experimental Medicine and Pediatrics (LEMP) and Infla-Med, research consortium of excellence, University of Antwerp, Antwerp, Belgium.
Stephanie A PetersDivision of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Joris G De ManLaboratory of Experimental Medicine and Pediatrics (LEMP) and Infla-Med, research consortium of excellence, University of Antwerp, Antwerp, Belgium.
Leslie C HassettMayo Clinic Libraries, Mayo Clinic, Rochester, Minnesota, USA.
Benedicte Y De WinterDivision of Gastroenterology, Laboratory of Experimental Medicine and Pediatrics, Universiteitsplein 1, Antwerp, 2610, Belgium.ORCID https://orcid.org/0000-0003-0327-6304
Madhusudan GroverDepartment of Medicine and Physiology, Enteric NeuroScience Program, 200 First St SW, Rochester, MN 55905, USA.ORCID https://orcid.org/0000-0001-5092-0831
Mayo Clinic · USUniversity of Antwerp · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimIrritable bowel syndrome (IBS) is a complex and heterogeneous disorder. Sensory, motor and barrier dysfunctions are the key physiological endophenotypes of IBS. Our aim is to review studies evaluating barrier dysfunction in adults and children with IBS, as well as to link those changes with IBS symptomatology and quality of life.

methodsA comprehensive and systematic review of multiple databases was performed up to March 2020 to identify studies comparing intestinal permeability in IBS patients with healthy controls. Both

resultsWe identified 66 studies, of which 27 used intestinal probes to quantify barrier function. The prevalence of barrier dysfunction differed between PI-IBS (17-50%), IBS-D (37-62%) and IBS-C (4-25%). At a group level, permeability was increased compared with healthy controls in IBS-D (9/13 studies) and PI-IBS (4/4 studies), but only a minority of IBS-C (2/7 studies) and not in the only IBS-M study. All four studies in children with IBS demonstrated loss of barrier function. A heterogeneous set of tight junction genes were found to be altered in small and large intestines of adults with IBS, but these have not been evaluated in children. Positive associations were identified between barrier dysfunction and bowel disturbances (6/9 studies), abdominal pain (9/13 studies), overall symptom severity (1/6 studies), depression and anxiety (1/1 study) and quality of life (1/4 studies). Fecal slurry or supernatants of IBS patients were found to induce barrier disruption in animal models (5/6 studies).

conclusionsBarrier dysfunction is present in a significant proportion of adult and all pediatric IBS studies, especially in the IBS-D and PI-IBS subtype. The majority of studies indicated a positive association between loss of barrier function and symptoms such as abdominal pain and changes in the bowel function.

Indexed as

functional gastrointestinal disordersimmune cellsmicrobiomeoccludinzonula occludens

Identifiers

PMID33717210
PMCPMC7925957
OpenAlexW3135713284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.